Integrated Immune Engineering for Poor Prognosis Cancers
综合免疫工程治疗预后不良的癌症
基本信息
- 批准号:10270392
- 负责人:
- 金额:$ 192.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-16 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAntitumor ResponseApoptosisAreaBenefits and RisksBiomedical EngineeringBiophysicsBloodCAR T cell therapyCancer ControlCancer PatientCancer PrognosisCellsChemicalsClinicalClinical TrialsCollaborationsComplexComputersDevelopmentDiagnosisDiffuseEconomicsEffectivenessEngineeringEnvironmentExplosionFailureGeneticGenetic EngineeringGenetically Engineered MouseGenome engineeringGlioblastomaGrowthHealth BenefitImageImmuneImmune responseImmune systemImmunocompetentImmunologicsImmunologistImmunooncologyImmunotherapeutic agentImmunotherapyIn VitroInfiltrationLiquid substanceMalignant NeoplasmsMalignant neoplasm of brainMalignant neoplasm of pancreasMeasuresMechanicsMicrofabricationModelingOncologyPancreatic Ductal AdenocarcinomaPatientsPharmacologyPhasePhysicsPlantsProcessPrognosisRiskSignal TransductionSolid NeoplasmStreamSystemT-LymphocyteTechnologyTestingTherapy trialTimeTissuesTranslationsTumor-infiltrating immune cellsanti-tumor immune responsebasebiophysical modelcancer cellcancer therapycell motilityclinical riskcomputational platformcostcytotoxicengineered T cellsexhaustionhigh resolution imaginghigh riskimmunoengineeringimmunotherapy clinical trialsimprovedin vivolive cell microscopymodel developmentmodels and simulationnanoscaleoptical imagingoptimismpatient populationphysical sciencepre-clinical assessmentpre-clinical researchpreclinical developmentprogramsresponsesuccesstumortumor immunologytumor progression
项目摘要
ABSTRACT
A key limitation to effective immunotherapy is the physical access of immune cells to the cancer cells. We
propose to develop a multiscale tumor simulator to predict tumor dynamics based on immune and cancer
cell migration and net proliferation as measured quantitatively from live cell microscopy. The tumor
simulator will be developed by biomedical engineers working in close collaboration with immunologists and
genetic engineers who are developing immunotherapies for pancreatic ductal adenocarcinoma and
glioblastoma. The tumor simulator will be a computational platform that will help guide immunotherapy
development and so will evolve to become an immunotherapy simulator. In addition, we will integrate state-
of-the-art genome engineering and microenvironmental engineering to bring a full suite of engineering
approaches to bear on the simulator development. Together, the simulator will be used to make
quantitative, testable predictions that are then tested experimentally using pharmacological and genetic
perturbations. By iterative model development we will test our central hypothesis that immune cell proximity
is a major determinant of effective anti-tumoral immune response, and limiting to effective immunotherapy
of solid tumors. Altogether, our Program Project will develop a comprehensive biophysics-based simulator
to predict tumor progression and accelerate immunotherapy development.
摘要
有效免疫疗法的一个关键限制是免疫细胞对癌细胞的物理访问。我们
我建议开发一个多尺度肿瘤模拟器,以预测基于免疫和癌症的肿瘤动力学
如活细胞显微镜定量测量的细胞迁移和净增殖。肿瘤
模拟器将由生物医学工程师与免疫学家密切合作开发,
正在开发胰腺导管腺癌免疫疗法的基因工程师,
胶质母细胞瘤肿瘤模拟器将是一个计算平台,将有助于指导免疫治疗
开发,因此将演变为免疫治疗模拟器。此外,我们将整合国家-
最先进的基因组工程和微环境工程,
模拟器开发的方法。总之,模拟器将用于使
定量的,可测试的预测,然后使用药理学和遗传学实验测试
扰动通过迭代模型开发,我们将测试我们的中心假设,即免疫细胞接近
是有效抗肿瘤免疫应答的主要决定因素,并限制有效的免疫治疗
实体肿瘤的总而言之,我们的计划项目将开发一个全面的基于生物制药学的模拟器
预测肿瘤进展并加速免疫疗法的发展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID ANDREW LARGAESPADA其他文献
DAVID ANDREW LARGAESPADA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID ANDREW LARGAESPADA', 18)}}的其他基金
Integrated Immune Engineering for Poor Prognosis Cancers
综合免疫工程治疗预后不良的癌症
- 批准号:
10700921 - 财政年份:2021
- 资助金额:
$ 192.1万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10439480 - 财政年份:2020
- 资助金额:
$ 192.1万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10653687 - 财政年份:2020
- 资助金额:
$ 192.1万 - 项目类别:
Uncovering treatment targets for peripheral nerve sheath tumor progression in NF1
发现 NF1 周围神经鞘瘤进展的治疗靶点
- 批准号:
10247078 - 财政年份:2020
- 资助金额:
$ 192.1万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10488079 - 财政年份:2019
- 资助金额:
$ 192.1万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10465297 - 财政年份:2019
- 资助金额:
$ 192.1万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10023258 - 财政年份:2019
- 资助金额:
$ 192.1万 - 项目类别:
Recurrent Tumor-Specific Alternately Processed Transcripts as a Source of Neoantigens for NF1-associated Malignant Peripheral Nerve Sheath Tumor Immunoprevention
复发性肿瘤特异性交替加工转录本作为 NF1 相关恶性周围神经鞘肿瘤免疫预防的新抗原来源
- 批准号:
10662510 - 财政年份:2019
- 资助金额:
$ 192.1万 - 项目类别:
Center for Modeling Tumor Cell Migration Mechanics
肿瘤细胞迁移机制建模中心
- 批准号:
9901832 - 财政年份:2016
- 资助金额:
$ 192.1万 - 项目类别:
Center for Modeling Tumor Cell Migration Mechanics
肿瘤细胞迁移机制建模中心
- 批准号:
9753166 - 财政年份:2016
- 资助金额:
$ 192.1万 - 项目类别:
相似海外基金
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
通过间质局部消融免疫疗法增强全身抗肿瘤反应,与转移性胰腺肿瘤的免疫检查点疗法协同作用
- 批准号:
10580071 - 财政年份:2022
- 资助金额:
$ 192.1万 - 项目类别:
Development of new cancer treatment utilizing the enhancement of antitumor response caused by allo reaction
利用同种异体反应增强抗肿瘤反应开发新的癌症治疗方法
- 批准号:
20K17649 - 财政年份:2020
- 资助金额:
$ 192.1万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of CD4 T cells and APCs in the induction and maintenance of an effective antitumor response
CD4 T 细胞和 APC 在诱导和维持有效抗肿瘤反应中的作用
- 批准号:
nhmrc : 143674 - 财政年份:2001
- 资助金额:
$ 192.1万 - 项目类别:
NHMRC Project Grants
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
- 批准号:
2377164 - 财政年份:1997
- 资助金额:
$ 192.1万 - 项目类别:
ANTICD20 MEDIATED SIGNALING AND ANTITUMOR RESPONSE
ANTICD20 介导的信号传导和抗肿瘤反应
- 批准号:
2712876 - 财政年份:1997
- 资助金额:
$ 192.1万 - 项目类别: